Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Generic depression patch tested against brand in small study

NCT ID NCT06607744

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a generic selegiline skin patch works the same as the brand-name EMSAM patch. Twelve healthy adults wore both patches to measure how much drug got into their blood and to check for skin irritation. The goal was to see if the generic version is a safe and effective alternative.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

12 people

The number who actually took part.

Started

Feb 2025

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Local subjects participate in the Hospital Ampang, Malaysia

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject age between 18 to 55 years old with adequate contraception but without taking oral contraceptives. 2. Subject body weight ≤ 120 kg, with a BMI within 18-30 kg/m². 3. Subject is able to complete the clinical study including the follow-up. 4. Subject is capable of providing written informed consent. 5. Subjects are able and willing to follow the requirements of the study and wearing patches. Exclusion Criteria: 1. Breastfeeding female. 2. Pregnancy test positive female. 3. At rest systolic blood pressure outside 90-140 mmHg or diastolic blood pressure outside 50- 90 mmHg or orthostatic hypotension. 4. At rest sinus bradycardia defined as symptomatic heart rate \< 50 bpm, or asymptomatic heart rate \< 45 bpm; and sinus tachycardia defined as heart rate \> 100 bpm. 5. Clinically significant ECG abnormalities (PQ interval \> 0.2 s, Duration of the QRS complex \> 0.1 s, AV block). 6. QTc \> 450 ms for male and \> 460 ms for female. 7. A history of allergies, or any significant adverse reactions, to any medications, unless the clinician considers that they are not clinically significant. 8. Clinically significant medical history of eyes, ears, nose, throat, respiratory, cardiovascular, gastrointestinal, genitourinary, neurological, haematopoietic, lymphatic, endocrine, metabolic, dermatological, musculoskeletal, psychological, family history or surgical history. 9. Family history of sudden cardiac death or pheochromocytoma. 10. Clinically significant physical examination finding or psychiatric unstable conditions or psychiatric illness requiring treatment. 11. Clinically significant laboratory abnormalities. 12. Haemoglobin \< 12.0 g/dL for male and \< 11.0 g/dL for female at screening. 13. Total bilirubin \> 1.25 x upper limit of normal, ALT/AST \> 1.5 x upper limit of normal. 14. Hepatitis B, Hepatitis C or HIV positive. 15. Urine DOA test positive. 16. Breath alcohol test positive. 17. Any smoker with tobacco or electronic tobacco products. 18. A history of drug or substance abuse, including alcohol (≥ 14 units per week) within 6 months before consent taking (1 unit of alcohol equals approximately ½ pint \[285 mL\] of beer, 1 glass \[125 mL\] of wine, or 1 shot \[25 mL\] of spirit). 19. Taking selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or cough or cold medicine (e.g., dextromethorphan, pseudoephedrine) or using carbamazepine or oxcarbazepine, or using meperidine and analgesic agents such as tramadol, methadone, and propoxyphene, or using sympathomimetic agents. 20. Unable to refrain from taking any medications (including herbal remedies) within 7 days before dosing, with the exception of birth control medications and other medications deemed acceptable by the Investigator. 21. Clinically significant illness or injury or hospitalisation for any reason within 28 days before consent taking.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MDD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Ampang

    Ampang, Selangor, 68000, Malaysia

  • Sarawak General Hospital

    Samoran, Sarawak, 94300, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.